Featuring perspectives from Drs Neeraj Agarwal, Himisha Beltran, Fred Saad and A Oliver Sartor, moderated by Dr Alan Bryce. Published March 2, 2022. (Webinar Video Proceedings)
TARGET AUDIENCE
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of prostate cancer.
LEARNING OBJECTIVES
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue
AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue
HOW TO USE THIS CME ACTIVITY
Video Program: This CME activity consists of a video component.
CME credit is no longer available for this issue
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY & MODERATOR — The following faculty and moderator reported relevant financial relationships with ineligible entities:
FACULTY
Neeraj Agarwal, MD
Professor of Medicine
Senior Director for Clinical Research Innovation
Huntsman Cancer Institute Presidential Endowed Chair of Cancer Research
Director, Center of Investigational Therapeutics
Director, Genitourinary Oncology Program
Huntsman Cancer Institute, University of Utah (NCI-CCC)
Salt Lake City, Utah
Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Calithera Biosciences, Clovis Oncology, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, MEI Pharma Inc, Merck, Nektar, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Seagen Inc.
Himisha Beltran, MD
Associate Professor of Medicine
Lank Center for Genitourinary Oncology and the Division of Molecular and Cellular Oncology
Director of Translational Research, Medical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts
Advisory Committee: Astellas, Amgen Inc, Blue Earth Diagnostics, Foundation Medicine, Janssen Biotech Inc, Merck, Oncorus, Pfizer; Consulting Agreement: Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Contracted Research: Bristol-Myers Squibb Company, Janssen Biotech Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP.
Fred Saad, MD, FRCS
Professor and Chairman of Urology
Director of GU Oncology
Raymond Garneau Chair in Prostate Cancer
University of Montreal Hospital Center (CHUM)
Montréal, Québec
Advisory Committee and Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Myovant Sciences, Novartis, Pfizer Inc, Sanofi Genzyme; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Janssen Biotech Inc, Merck, Myovant Sciences, Novartis, Pfizer Inc, Sanofi Genzyme.
A Oliver Sartor, MD
Laborde Professor for Cancer Research
Medical Director, Tulane Cancer Center
Associate Dean for Oncology
Tulane Medical School
New Orleans, Louisiana
Consulting Agreements: Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bavarian Nordic, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Bristol-Myers Squibb Company, Clarity Pharmaceuticals, Clovis Oncology, Constellation Pharmaceuticals, Dendreon Pharmaceuticals Inc, EMD Serono Inc, Fusion Pharmaceuticals, ITM Isotopen Technologien München AG, Janssen Biotech Inc, Merck, Myovant Sciences, Myriad Genetic Laboratories Inc, Noria Therapeutics Inc, Novartis, Noxopharm, Pfizer Inc, Point Biopharma Inc, Progenics Pharmaceuticals Inc, Sanofi Genzyme, Telix Pharmaceuticals,TeneoBio, Theragnostics; Contracted Research: Advanced Accelerator Applications, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Constellation Pharmaceuticals, Endocyte Inc, Invitae, Janssen Biotech Inc, Lantheus, Merck, Progenics Pharmaceuticals Inc, TeneoBio; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Pfizer Inc, Myovant Sciences.
Moderator
Alan H Bryce, MD
Chair, Division of Hematology and Medical Oncology
Chair, Genitourinary Disease Group
Mayo Clinic
Phoenix, Arizona
Advisory Committee: Merck; Contracted Research: Janssen Biotech Inc.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Exelixis Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Merck.
Release date: March 2022
Expiration date: March 2023
(WIFI is recommended for best performance):